The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Open accessAbstract
The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years. We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (minimum inhibitory concentration 0.06 mug/ml). In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit. Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations. A single dose of R207910 inhibited mycobacterial growth for 1 week. Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 14 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 was extensively distributed to tissues, including lungs and spleen (Fig. 3A, table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These average concentrations were greater than that achieving optimal activity in established infection in mice.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Low MICs were also found for other mycobacterial species, including Mycobacterium bovis, Mycobacterium kansasii and Mycobacterium ulcerans, as well as species naturally resistant to many other anti-TB agents and involved in opportunistic infections, such as Mycobacterium avium complex (MAC), Mycobacterium abscessus, Mycobacterium fortuitum and Mycobacterium marinum (Table 1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 25 mg/kg, the activity of R207910 was significantly better than at 12.5 mg/kg (P = 0.005).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The bactericidal activity obtained by the RHZ combination after 2 months of therapy was matched by the combinations JHZ and RJZ after just 1 month of therapy.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, at 12.5 and 25 mg/kg, R207910 was significantly more active (P = 0.005) than 25 mg/kg isoniazid, a drug known for its strong, early bactericidal activity (Fig. 4A).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, the susceptibility of R207910-resistant M. tuberculosis strains remained unchanged to other anti-TB agents, including isoniazid, rifampin, streptomycin, amikacin, ethambutol and moxifloxacin.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To date, 20 molecules of the DARQ series have a minimum inhibitory concentration (MIC) below 0.5 µg/ml against M. tuberculosis H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data from a multiple-ascending-dose study have shown an increase (approximately by a factor of two) in AUC 0-24h from Day 1 to Day 14 of once-daily dosing at 50, 150 and 400 mg R207910, without substantial variation between subjects.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plasma levels associated with efficacy in mice are well tolerated in healthy human volunteers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclear
- Probably not a substantial claim. 3
- It may state two separate claims as one. 40
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The most active compound of the class, R207910, is a pure enantiomer with two chiral centers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“No accumulation of R207910 was observed after five daily oral doses, indicating that slow redistribution from tissues contributed to the relatively long half-lives in plasma.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the second study, the good tolerability was maintained; only one subject withdrew from the study, because of a urinary tract infection (unrelated to R207910) after seven doses at 150 mg/day.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When added to the first-line triple TB therapy combination RHZ, 25 mg/kg R207910 (J) increased the drop in bacterial load in the lungs by 2 log 10 after 1 month of therapy compared with standard RHZ treatment regimen, and a further 1 log 10 drop after 2 months.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximum plasma concentrations (C max ) of 0.40-0.54µg/ml with a single 6.25 mg/kg/dose were achieved within 1 hour and 1.1-1.3µg/ml with a 25 mg/kg/dose within 2-4 hours.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of adverse events reported (supporting online text), were considered possibly related to the study medication-placebo (seven of 18 subjects) or R207910 (20 of 36 subjects).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The AUC showed a better correlation with the dose than C max , reflecting limitations in rate of absorption at higher dosing regimens, as confirmed in a single-dose pharmacokinetic study comparing C max and AUC after 6.25, 25 and 100 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This anti-mycobacterial-specific spectrum differs from that of isoniazid, which has very poor activity against MAC.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies using oral treatment of R207910 for 5 days per week for 4 weeks, starting the day after inoculation, the minimal dose of R207910 that prevented mortality in nonestablished infection was 1.5 mg/kg, and the minimal effective dose (MED) preventing gross lung lesions was 6.5 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposure of M. tuberculosis in log-phase growth to concentrations of R207910 at 10-fold MIC resulted in a 3 log 10 reduction in bacterial counts after 12 days, indicating that R207910 has bactericidal activity in vitro (table S2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Complementation studies have verified that the mutant atpE gene is responsible for resistance to R207910, implying that the atpE gene product is the target of R207910 in mycobacteria.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The range of MICs for the international reference strain M. tuberculosis H37Rv and six fully antibiotic susceptible isolates was 0.03-0.120µg/ml (Table 1), versus 0.500 µg/ml for rifampin and 0.120 µg/ml for isoniazid (results not shown).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 30 isolates of MDR-TB tested were susceptible to 0.100 µg/ml of R207910, and 17 (57%) were susceptible to 0.010 µg/ml of R207910 (Table 2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pharmacokinetic results from the single-ascending-dose study suggested that R207910 is well absorbed after single oral administration, and the peak concentration was reached at 5 hours (median value) post-dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 had much higher MICs for Corynebacterium and Helicobacter pylori (MIC 4.0 µg/ml), and especially for other organisms such as Gram-positive Nocardia, Streptococcus pneumoniae, Staphylococcus aureus and Enterococcus faecalis, or Gram-negative Escherichia coli and Haemophilus influenzae (table S1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Half-lives ranged from 43.7 to 64 hours in plasma and 28.1 to 92 hours in tissues (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of drugs included in the World Health Organization's firstline tuberculosis treatment regimen (rifampin, isoniazid and pyrazinamide) with R207910 accelerates bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The DARQ R207910 is a member of a new chemical class of anti-mycobacterial agents and has an MIC equal to or lower than that of reference compounds.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A single dose of 50 mg/kg R207910 in the non-established infection murine model of TB infection resulted in a bacteriostatic effect (0.5 log 10 drop in bacterial count in the lungs), which lasted for 8 days-a similar effect to that of rifapentine (10 mg/kg) (Fig. 3B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In established infection (treatment beginning 12-14 days after inoculation when bacterial load was 5.94 log 10 CFU), 25 mg/kg R207910 as monotherapy was at least as active as the triple combination therapy (rifampin [R] + isoniazid [H] + pyrazinamide [Z]), and more active than rifampin alone (Fig. 4B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (MIC 0.06 µg/ml).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean AUC 0-24h values were 7.91, 24 and 52 µg/hour/ml at steady state, corresponding to average concentrations of 0.33, 1.0 and 2.2 µg/ml across a dosing interval, with 50, 150 and 400 mg/day, respectively.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pharmacokinetics of R207910 were linear up to the highest dose tested (700 mg); both C max and AUC increased proportionally with the administered dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The two point mutations identified (D32V for M. smegmatis and A63P for M. tuberculosis) are both in the membrane-spanning domain region of the protein.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Areas under the concentration-time curve (AUCs) ranged from 5.0 to 5.9 µg/hour/ml with a 6.25 mg/kg/dose and 18.5 to 19.4 µg/hour/ml with a 25 mg/kg/dose (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“From selection experiments, the proportion of resistant mutants that emerged was 5 x 10 -7 and 2 x 10 -8 at four-fold MIC, and 5 x 10 -8 and 1 x 10 -8 at eight-fold MIC for M. tuberculosis and M. smegmatis, respectively (8).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [8] 8. Details of materials and methods and supporting online text are available as supporting material on Science Online.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of each of the three first-line drugs with R207910 resulted in a dramatic increase in potency, leading to complete culture conversion of the lungs in some animals after only 2 months of treatment.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 has potent early bactericidal activity in the nonestablished murine TB model, matching or exceeding that of isoniazid (Fig. 4A), which is consistent with in vitro observations pointing to a bactericidal activity.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, the bactericidal potency seen upon administration of a single dose of 100 mg/kg R207910 in vivo was similar to the effect seen upon continuous exposure of cultures to 0.6 µg/ml (or 10-fold the median MIC of the H37Rv strain) in vitro, giving a first indication of the pharmacodynamics of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the minimal bactericidal dose was very close to the MED, a finding confirming timedependent, rather than concentration-dependent, activity of R207910 in vitro.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data suggest that maintaining average plasma levels of 0.3 µg/ml/day across a dosing interval, which is achieved with a 100 mg/kg/week dose, is necessary to achieve optimal effect of monotherapy in mice infected with strain H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The killing effect was not increased by higher concentrations of the compound, suggesting the killing was time-dependent rather than concentration-dependent.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although current first-line anti-TB drug regimens can achieve more than 99% efficacy, this is often reduced because of drug resistance (5).”
What the sources say
- Not matchedcites [5] 5. R. J. O'Brien, P. P. Nunn, Am. J. Respir. Crit. Care Med. 163, 1055 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Not matched
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Structurally and mechanistically, DARQs are very different from both fluoroquinolones (including methoxyquinolones) and other quinoline classes, including mefloquine and its analogs 4-methylquinolines and 4quinolylhydrazones (9-13).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [9] 9. R. Jain, B. Vaitilingam, A. Nayyar, P. B. Palde, Bioorg. Med. Chem. Lett. 13, 1051 (2003).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [10] 10. C. M. Kunin, W. Y. Ellis, Antimicrob. Agents Chemother. 44, 848 (2000).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [11] 11. M. R. Barbachyn, S. J. Brickner, Patent (International Publication Number: WO 93/09103, International Publication Date: 13 May, 1993, International Application Number: PCT/US92/08267, International Filing Date: 1992).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [12] 12. L. Savini, L. Chiasserini, A. Gaeta, C. Pellerano, Bioorg. Med. Chem. 10, 2193 (2002). / www.sciencexpress.org /9 December 2004 / Page 4/ 10.1126/science.1106753
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [13] 13. S. Vangapandu, M. Jain, R. Jain, S. Kaur, P. P. Singh, Bioorg. Med. Chem. 12, 2501 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The long half-lives and consequently prolonged exposure are important factors determining the duration of activity in vivo and provide a rationale for less frequent dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A comparison of the sequences of ATP synthases of different bacteria and of eukaryotic ATP synthase provides a rationale for the specificity of the antibacterial spectrum and, to a lesser extent, the safety profile of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the distinct target of R207910 means that there is no crossresistance with existing anti-TB drugs, and our studies verified it is as effective against MDR strains as it is against fully antibiotic-susceptible strains.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Inhibition of ATP synthase function may lead to ATP depletion and imbalance in pH homeostasis, both contributing to decreased survival (15,16).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [15] 15. M. Rao, T. L. Streur, F. E. Aldwell, G. M. Cook, Microbiology 147, 1017 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [16] 16. G. Deckers-Hebestreit, K. Altendorf, Annu. Rev. Microbiol. 50, 791 (1996).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These are all attributes that are valuable for treatment of chronic infections and they may also be important for the development of simpler dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [17] 17. E. L. Nuermberger et al., Am. J. Respir. Crit. Care Med. 169, 421 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The paper relies on this without support.
No tuberculosis-specific drugs have been discovered in 40 years.
“Tuberculosis has been increasing significantly on a worldwide basis over the past decade, but no tuberculosisspecific drugs have been discovered in 40 years.”
The paper relies on this without support.
The murine TB model is predictive of human TB treatment outcomes.
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TMC207 is bactericidal towards most species of mycobacteria (109), but is only bacteriostatic against M. avium (118) and M. smegmatis (Berney and Cook, unpublished data).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When mycobacterial cells (growing or non-growing) are treated with TMC207, time-dependent (not dose-dependent) killing is observed (109).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M. smegmatis was used for the initial compound screening that identified diarylquinoline (later named Bedaquiline) as a specific inhibitor of mycobacterial ATP synthase in 2005, which ended a 40-year dearth in anti-TB drug discovery (147).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen.”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Citations
Cites
Amino acid substitution matrices from protein blocks.
Henikoff, S., & Henikoff, J. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10915 · Cited by 6,218
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Comparing the Means of Several Groups
Godfrey, K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132305 · Cited by 740
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S. K., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 315
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis
Siddiqi, S. H., Libonati, J. P., & Middlebrook, G. (1981) · Journal of Clinical Microbiology · doi:10.1128/jcm.13.5.908-912.1981 · Cited by 242
The Need for New Drugs against Tuberculosis
O'BRIEN, R. J., & NUNN, P. P. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2007122 · Cited by 221
THE F0F1-TYPE ATP SYNTHASES OF BACTERIA: Structure and Function of the F0 Complex
Deckers-Hebestreit, G., & Altendorf, K. (1996) · Annual Review of Microbiology · doi:10.1146/annurev.micro.50.1.791 · Cited by 195
Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG
Rao, M., Streur, T. L., Aldwell, F. E., & Cook, G. M. (2001) · Microbiology · doi:10.1099/00221287-147-4-1017 · Cited by 148
Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones
Savini, L., Chiasserini, L., Gaeta, A., & Pellerano, C. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00071-8 · Cited by 134
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,100 of 2,159
Schmitt, E. K., Riwanto, M., Sambandamurthy, V. K., Roggo, S. P., Miault, C., Zwingelstein, C., Krastel, P., Noble, C. G., Beer, D., Rao, S. P. S., et al. (2011) · Angewandte Chemie · doi:10.1002/ange.201101740 · Cited by 26
Unique GMP‐binding site in Mycobacterium tuberculosis guanosine monophosphate kinase
Hible, G., Christova, P. K., Renault, L., et al. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20662 · Cited by 25
“One of the research strategies in fighting against this disease is the identification of new targets for more effective drugs.(1)”
BackgroundProgress and hindrances in tuberculosis vaccine development
Doherty, T. M., & Rook, G. A. W. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68389-x · Cited by 25
Tong, E., Wu, Q., Chen, Y., Liu, Z., Zhang, M., Zhu, Y., Wu, K., Pan, J., 潘军航, & Jiang, J. (2023) · Antibiotics · doi:10.3390/antibiotics12091389 · Cited by 27
“The World Health Organization (WHO) has estimated that a quarter of the world’s population is infected with MTB [1].”
BackgroundInfluentialOfori-Anyinam, B., Hamblin, M., Coldren, M. L., Li, B., Mereddy, G., Shaikh, M., Shah, A., Grady, C. A., Ranu, N., Lu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53933-8 · Cited by 23
Targeting de novo purine biosynthesis for tuberculosis treatment
Lamprecht, D. A., Wall, R. J., Leemans, A., Truebody, B., Sprangers, J., Fiogbe, P., Davies, C., Wetzel, J., Daems, S., Pearson, W., et al. (2025) · Nature · doi:10.1038/s41586-025-09177-7 · Cited by 24
Antituberculosis drugs in children
Schaaf, H. S., Garcia‐Prats, A. J., & Donald, P. R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.164 · Cited by 24
“inhibitor, was the first new anti-TB agent developed in nearly 40 years.(76) Conditional approval for the use of BDQ for the”
BackgroundKalia, D., S., A. K. K., Meena, G., et al. (2015) · MedChemComm · doi:10.1039/c5md00131e · Cited by 24
Zheng, Q., Ding, Q., Wang, C., et al. (2015) · Tetrahedron · doi:10.1016/j.tet.2015.12.060 · Cited by 24
Effect of bedaquiline on the functions of rat liver mitochondria
Belosludtsev, K. N., Belosludtseva, N. V., Talanov, E. Y., Tenkov, K. S., Starinets, V. S., Agafonov, A. V., Pavlik, L. L., & Dubinin, M. V. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.06.012 · Cited by 24
Soto, R., Pérez‐Herrán, E., Rodríguez, B., Duma, B. M., Cacho, M., Mendoza-Losana, A., Lelièvre, J., Barros-Aguirre, D., Ballell, L., Cox, L. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31157-3 · Cited by 25
Yang, J., Pang, Y., Zhang, T., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.07.044 · Cited by 24
Pieterman, E. D., Keutzer, L., van der Meijden, A., van den Berg, S., Wang, H., Zimmerman, M. D., Simonsson, U. S. H., Bax, H. I., & de Steenwinkel, J. E. M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab043 · Cited by 24
“The observed dose-dependent activity of bedaquiline was comparable to other murine studies [17, 18].”
ResultCurrent Molecular Therapeutic Agents and Drug Candidates for Mycobacterium abscessus
Quang, N. T., & Jang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724725 · Cited by 24
Gao, F., Li, J., Ahmad, T., et al. (2022) · Science China Chemistry · doi:10.1007/s11426-022-1387-7 · Cited by 24
Targeting mycobacterial membranes and membrane proteins: Progress and limitations
Kumar, G., & Kapoor, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117212 · Cited by 28
The Discovery of Medicines for Rare Diseases
Swinney, D. C., & Xia, S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.65 · Cited by 25
Antituberculosis therapy for 2012 and beyond
Lauzardo, M., & Peloquin, C. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657176 · Cited by 24
“However, it must be kept in mind that TMC207 has timedependent bactericidal effects, and that if the study is carried out longer or used in combination with PZA more rapid killing of organisms would be observed.”
InfluentialCell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis
McNeil, M. B., Chettiar, S. N., Awasthi, D., & Parish, T. (2019) · Access Microbiology · doi:10.1099/acmi.0.000006 · Cited by 22
“Since BDQ disrupts ATP generation, it could have negative effects on ATP-dependent transport mechanisms, which might be independent of changes in cell wall structure.”
BackgroundInfluentialEnergetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T. E., & Berney, M. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch20 · Cited by 23
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Woods, G. L., Lin, S.-Y. G., & Desmond, E. P. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch76 · Cited by 24
After decades of drought, new drug possibilities flood TB pipeline
Check, E. (2007) · Nature Medicine · doi:10.1038/nm0307-266 · Cited by 24
Cramming More Sequencing Reactions onto Microreactor Chips
Leamon, J. H., & Rothberg, J. M. (2007) · Chemical Reviews · doi:10.1021/cr068297s · Cited by 24
Ferreira, L. A. P., Caruso, L., Nadur, N. F., Franco, D. P., Sousa, G. L. S., Lacerda, R. B., & Kümmerle, A. E. (2026) · ACS Omega · doi:10.1021/acsomega.5c08365 · Cited by 28
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
Hu, M., Zheng, C., & Gao, F. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s121630 · Cited by 23
“Since the antimicrobial action of bedaquiline and delamanid is exposure-dependent, 20,97 it is necessary that target exposures be ensured.”
Erber, J., Weidlich, S., Tschaikowsky, T., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05075-7 · Cited by 23
Dousa, K. M., Kurz, S. G., Bark, C. M., Bonomo, R. A., & Furin, J. J. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.06.001 · Cited by 22
Alsayed, S. S. R., Lun, S., Payne, A. D., Bishai, W. R., & Gunosewoyo, H. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104486 · Cited by 22
“11 μM [58]) against both DS- and DR-TB.”
BackgroundChen, B.-C., Ding, Z., Dai, J.-S., Chen, N.-P., Gong, X., Ma, L., & Qian, C. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.647289 · Cited by 24
“tuberculosis by specifically inhibiting F1F0-ATP synthase (Andries, 2005; Koul et al., 2007; Sarathy et al., 2019).”
BackgroundShetye, G. S., Choi, K. B., Kim, C., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00282-21 · Cited by 23
Derivation of a Precise and Consistent Timeline for Antibiotic Development
Stennett, H. L., Back, C. R., & Race, P. R. (2022) · Antibiotics · doi:10.3390/antibiotics11091237 · Cited by 23
“Organoarsenics 1909 [42] 1910 [42] 1912 [43] Penicillins 1928 [44] 1941 [45] 1945 [46] Sulfonamides 1932 [42] 1935 [47] 1939 [48] Sulfones 1937 [49] 1943 [50] 1963 [35] Polypeptides 1939 [51] 1941 [52] N/A 1 [25] Salicylates 1940 [53] 1944 [54] 1949 [55] Aminoglycosides 1943 [56] 1946 [57] 1946 [58] Phenazines 1943 [5…”
Noise in a Metabolic Pathway Leads to Persister Formation in Mycobacterium tuberculosis
Quigley, J., & Lewis, K. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02948-22 · Cited by 25
“…tolerance in M. tuberculosis In order to examine a causal link between a low energy state and persister formation in M. tuberculosis, we took advantage of the antibiotic bedaquiline that specifically inhibits the mycobacterial F1F0 ATP synthase by binding to its C-subunit (Andries et al., 2005).”
BackgroundRani, C., Mehra, R., Sharma, R., Chib, R., Wazir, P., Nargotra, A., & Khan, I. A. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.06.003 · Cited by 23
“A number of new anti-TB drugs have been developed in recent years and some of those are currently being evaluated in different stages of clinical trial [35,36].”
BackgroundEngström, A. (2015) · Scandinavian Journal of Infectious Diseases · doi:10.3109/23744235.2015.1061205 · Cited by 22
“Andries K , Verhasselt P , Guillemont J , Gohlmann HW , [151] Neefs JM , Winkler H , et al .”
BackgroundThe open book of infectious diseases
Sassetti, C. M., & Rubin, E. J. (2007) · Nature Medicine · doi:10.1038/nm0307-279 · Cited by 23
Knudson, S. E., Awasthi, D., Kumar, K., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv226 · Cited by 23
Poen, S., Nakatani, Y., Opel‐Reading, H. K., Lassé, M., Dobson, R. C. J., & Krause, K. L. (2016) · Biochemical Journal · doi:10.1042/bcj20160186 · Cited by 24
Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis
Unissa, A. N., Hassan, S., Kumari, V. I., et al. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.04.005 · Cited by 23
Jung, I., Ha, N., Lee, S.-C., et al. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.031 · Cited by 23
Chibale, K., Masimirembwa, C. M., & Davies-Coleman, M. (2012) · Springer eBooks · doi:10.1007/978-3-642-28175-4 · Cited by 25
Wilson, C. R., Gessner, R. K., Moosa, A., Seldon, R., Warner, D. F., Mizrahi, V., de Melo, C. S., Simelane, S. B., Nchinda, A. T., Abay, E. T., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01347 · Cited by 23
Tükenmez, H., Edström, I., Ummanni, R., Fick, S. B., Sundin, C., Elofsson, M., & Larsson, C. (2019) · Scientific Reports · doi:10.1038/s41598-018-37176-4 · Cited by 23
Sankhe, K., Khan, T., Bhavsar, C., Momin, M., & Omri, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1609937 · Cited by 18
Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China
Xu, P., Wu, J., Yang, C., et al. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.02.008 · Cited by 23
Growth hormone deficiency and supplementation at in-vitro fertilisation.
Rajesh, H., Yong, Y. Y., Zhu, M., et al. (2007) · PubMed · Cited by 23
Self-citationIslam, M. M., Alam, M. S., Liu, Z., Khatun, M. S., Yusuf, B., Hameed, H. M. A., Tian, X., Chhotaray, C., Basnet, R., Tadesse, H. A., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1304857 · Cited by 30
“%) than newly diagnosed patients (33.3%), suggesting this attributed to the previous medical history requires for the use BDQ. Importantly, the mechanism of BDQ resistance in Mtb mainly involves three genes, namely, the atpE (128), Rv0678 (52), and pepQ (54) genes.”
BackgroundInfluentialSaha, P., Sau, S., Kumar, R., Kalia, N. P., & Kumar, D. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00118d · Cited by 22
Krah, A., Zarco‐Zavala, M., & McMillan, D. G. G. (2018) · Open Biology · doi:10.1098/rsob.170275 · Cited by 22
“The drug bedaquiline (BDQ; previously known as compound TMC207) has been shown to be a novel antibiotic compound against tuberculosis [1], and to bind to a purified preparation of M.”
BackgroundDevelopment of new drug-regimens against multidrug-resistant tuberculosis
Vasava, M. S., Nair, S., Rathwa, S. K., Patel, D. B., & Patel, H. D. (2018) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2018.07.004 · Cited by 22
Deletion of pknG Abates Reactivation of Latent Mycobacterium tuberculosis in Mice
Khan, M. Z., & Nandicoori, V. K. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02095-20 · Cited by 22
Novel treatments in multidrug-resistant tuberculosis
Mondoni, M., Saderi, L., & Sotgiu, G. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.05.007 · Cited by 22
3-Arylsulfonylquinolines from N-Propargylamines via Cascaded Oxidative Sulfonylation Using DABSO
Mathuri, A., Pramanik, M., & Mal, P. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c00499 · Cited by 22
Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase
Krah, A., Grüber, G., & Bond, P. J. (2022) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2022.09.001 · Cited by 22
Why Matter Matters: Fast-Tracking Mycobacterium abscessus Drug Discovery
Ganapathy, U. S., & Dick, T. (2022) · Molecules · doi:10.3390/molecules27206948 · Cited by 22
“By targeting the proton pump of the mycobacterial F-ATP synthase (AtpE), this compound blocks the bacterium’s ability to produce ATP, killing the bacterium both in vitro and in mouse models [93,94].”
BackgroundZhu, R., Shang, Y., Chen, S., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01372-22 · Cited by 22
Genetic engineering of Mycobacterium tuberculosis: A review
Lamrabet, O., & Drancourt, M. (2012) · Tuberculosis · doi:10.1016/j.tube.2012.06.002 · Cited by 21
Tuberculosis: from genome to vaccine
de Jonge, M. I., Brosch, R., Brodin, P. M., Demangel, C., & Cole, S. T. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.4.541 · Cited by 22
Kotapalli, S. S., Nallam, S. S. A., Nadella, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144018 · Cited by 22
Boot, M., Jim, K. K., Liu, T., Commandeur, S., Lü, P., Verboom, T., Lill, H., Bitter, W., & Bald, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-10944-4 · Cited by 25
Li, S., Wu, H.-T., Liu, Y., Jiang, Y.-Y., Zhang, Y., Liu, W., Zhu, K., Li, D., & Zhang, H. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01025 · Cited by 22
“tuberculosis when it was treated by F1Fo-ATP synthase inhibitor (Andries et al., 2005; Koul et al., 2014).”
BackgroundMethodMuronetz, V. I., Melnikova, A. K., Barinova, K. V., & Schmalhausen, E. V. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919110051 · Cited by 22
Introduction: Novel insights into TB research and drug discovery
Grüber, G. (2020) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2020.02.003 · Cited by 22
Improved Synthesis and Isolation of Bedaquiline
Lubanyana, H., Arvidsson, P. I., Govender, T., et al. (2020) · ACS Omega · doi:10.1021/acsomega.9b04037 · Cited by 22
Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors
Liu, Y., Hu, X., Chai, X., et al. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.003 · Cited by 22
SNP Discovery by Transcriptome Pyrosequencing
Barbazuk, W. B., & Schnable, P. S. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-065-2_15 · Cited by 22
Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending
Salfinger, M., & Migliori, G. B. (2015) · European Respiratory Journal · doi:10.1183/09031936.00199814 · Cited by 21
Peng, F., Liu, J., Li, L., et al. (2017) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201701472 · Cited by 21
Kienle, M., Eisenring, P., Stoessel, B., Horlacher, O. P., Hasler, S., van Colen, G., Hartkoorn, R. C., Vocat, A., Cole, S. T., & Altmann, K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01457 · Cited by 22
Tran, H. T., Solnier, J., Pferschy‐Wenzig, E., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9070390 · Cited by 21
Lu, G., Tong, A. S. T., Conole, D., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115784 · Cited by 21
Hawkins, P. M. E., Hoi, D. M., Cheung, C., Wang, T., Quan, D. H., Sasi, V. M., Liu, D. Y., Linington, R. G., Jackson, C. J., Oehlers, S. H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02122 · Cited by 21
Nguyen, P. P., Kado, T., Prithviraj, M., Siegrist, M. S., & Morita, Y. S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100262 · Cited by 21
ATP Synthase: The Right Size Base Model for Nanomotors in Nanomedicine
Ahmad, Z., & Cox, J. L. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/567398 · Cited by 22
“cause resistance to the tuberculosis drug diarylquinoline [100, 101].”
Bakal, R. L., & Gattani, S. G. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.054 · Cited by 21
The Medicinal Chemistry of Tuberculosis Chemotherapy
Marriner, G. A., Nayyar, A., Uh, E., Wong, S. Y., Mukherjee, T., Via, L. E., Carroll, M., Edwards, R. L., Gruber, T. D., Choi, I., et al. (2011) · Topics in medicinal chemistry · doi:10.1007/7355_2011_13 · Cited by 23
“In humans, Cmax is reached in 4–5 h [164, 173, 183], and a daily dose of 400 mg administered daily for 7 days results in a Cmax of 10 mM [183].”
BackgroundMethodInfluentialNovel and revisited approaches in antituberculosis drug discovery
Herrmann, J. E., Rybniker, J., & Müller, R. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.023 · Cited by 21
Hu, X., Wan, B., Liu, Y., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00410 · Cited by 21
Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines
Maslov, D. A., Korotina, А. V., Shur, K. V., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.081 · Cited by 21
Li, P., Wang, B., Li, G., Fu, L., Zhang, D., Lin, Z., Huang, H., & Lu, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112538 · Cited by 23
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
Appetecchia, F., Consalvi, S., Scarpecci, C., Biava, M., & Poce, G. (2020) · Pharmaceuticals · doi:10.3390/ph13090227 · Cited by 21
“It was identified through a whole-cell phenotypic screening and exhibited an outstanding bactericidal activity against replicating and dormant Mtb, no cross-resistance with other anti TB drugs, and a sterilizing activity in animal models [91].”
BackgroundAntimicrobial activity of newly synthesized methylsulfanyl-triazoloquinazoline derivatives
Al‐Salahi, R. A., Marzouk, M., Awad, G. E. A., Al-Omar, M. A., & Ezzeldin, E. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12039 · Cited by 21
“Finally, reaction of 6 with sodium alkoxides furnished the [1,2,4]triazoloquinazolines 17 and 18 (Figure 1).”
BackgroundMethodInfluentialA case for passive immunoprophylaxis against tuberculosis
Reljić, R., & Iványi, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70658-2 · Cited by 21
A High-Throughput Cidality Screen for Mycobacterium Tuberculosis
Kaur, P., Ghosh, A., Krishnamurthy, R. V., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117577 · Cited by 21
“, TMC 207 or Bedaquiline, an anti-TB compound) [6].”
New drugs to treat tuberculosis
Swindells, S. (2012) · F1000 Medicine Reports · doi:10.3410/m4-12 · Cited by 21
“Used alone in the mouse model, TMC207 was more active than conventional multidrug therapy combined, and produced complete sterilization at 2 months in combination therapy [29].”
BackgroundMethodJiang, B., Hu, L., & Gui, W. (2014) · RSC Advances · doi:10.1039/c4ra00821a · Cited by 21
Fair, R. J., McCoy, L. S., Hensler, M. E., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201402175 · Cited by 21
Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis
Ahmad, S., & Mokaddas, E. M. (2010) · Respiratory Medicine CME · doi:10.1016/j.rmedc.2010.08.001 · Cited by 21
Les cas de tuberculose maladie declares en France en 2006
Antoine, D., & Che, D. (2008) · Cited by 21
Khare, G., Kumar, P., & Tyagi, A. K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01444-13 · Cited by 20
Wride, D. A., Pourmand, N., Bray, W. M., Kosarchuk, J. J., Nisam, S. C., Quan, T. K., Berkeley, R. F., Katzman, S. J., Hartzog, G. A., Dobkin, C., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb00146j · Cited by 18
Exploring prospects of novel drugs for tuberculosis
Pieters, J., Janssen, S., Jayachandran, Khathi, Zinsstag, J., & Grobusch, M. P. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s34006 · Cited by 20
A review of recent advances in anti-tubercular drug development
Umumararungu, T., Mukazayire, M.-J., Mpenda, M., et al. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.07.017 · Cited by 20
The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection
Li, G., Oliveira, D. M. P. D., & Walker, M. J. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111661 · Cited by 21
An Introduction on Evolution of Azole Derivatives in Medicinal Chemistry
Kabi, A. K., Sravani, S., Gujjarappa, R., Garg, A., Vodnala, N., Tyagi, U., Kaldhi, D., Ravichandiran, V., Gupta, S., & Malakar, C. C. (2022) · Materials horizons · doi:10.1007/978-981-16-8399-2_4 · Cited by 22
Adolph, C., Cheung, C., McNeil, M. B., Jowsey, W. J., Williams, Z. C., Hards, K., Harold, L. K., Aboelela, A., Bujaroski, R. S., Buckley, B. J., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.12.002 · Cited by 21
Ang, W., Ye, W., Sang, Z., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.025 · Cited by 20
Synthesis and antibacterial activity of monocyclic 3-carboxamide tetramic acids
Jeong, Y., & Moloney, M. G. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.224 · Cited by 20
Bald, D., & Koul, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.007 · Cited by 20
Nathan, C. (2008) · Science · doi:10.1126/science.1167452 · Cited by 21
Clinical implications of the global multidrug-resistant tuberculosis epidemic
Kumar, K., & Abubakar, I. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-s37 · Cited by 20
Metadata
- Authors
- Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., & Jarlier, V.
- Affiliations
- Johnson & Johnson (United Kingdom) (GB)
- Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
- Corresponding author
- Andries, Koen
- Lounis, Nacer
- Venue
- Science
- Published
- 2005-01-14
- Volume
- 307
- Issue
- 5707
- Pages
- 223-227
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2158658436
- Cited by
- 2,191
- References
- 13
- Citations by year
- 2026: 63 · 2025: 98 · 2024: 103 · 2023: 106 · 2022: 111 · 2021: 98 · 2020: 136 · 2019: 141 · 2018: 102 · 2017: 124 · 2016: 120 · 2015: 129 · 2014: 140 · 2013: 106 · 2012: 102
- FWCI
- 27.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- diarylquinolines, Mycobacterium tuberculosis, tuberculosis drug resistance, ATP synthase inhibition, proton pump, bactericidal activity, combination therapy, isoniazid
- MeSH terms
- Amino Acid Sequence, Animals, Antitubercular Agents, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Therapy, Combination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
